<DOC>
	<DOCNO>NCT01073839</DOCNO>
	<brief_summary>OBJECTIVES Primary objective : The primary objective trial determine safety adjuvant treatment cisplatin plus gemcitabine period 6 month curative resection cholangiocellular carcinoma Secondary objective : Secondary objective trial ass feasibility efficacy adjuvant therapy determine duration response pattern failure compare historical control without postoperative treatment Exploratory objective : To obtain blood sample tumor tissue resection establishment characterization new cholangiocarcinoma cell line tumor antigen . Other aims identification tumor specific antibody blood sample , characterization tumor antigens consecutive development new specific immunological therapy , e.g . cancer-testis antigen ( CTA ) tumor vaccination . - Trial medicinal product</brief_summary>
	<brief_title>Adjuvant Cisplatin Plus Gemcitabine Operable Cholangiocellular Carcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion 1 . Histologically cytologically confirm adenocarcinoma biliary tract ( intrahepatic hilar tumor ) . Carcinomas involve gall bladder allow . 2 . Macroscopically complete resection within 8 week start chemotherapy . 3 . Written informed consent . 4 . Health status : WHO performance status ( PS ) 01 5 . Age &gt; 18 year 6 . Adequate renal function ( creatinine clearance ≥ 60 ml/min , calculate accord formula CockcroftGault ) 7 . Adequate hepatic function ( bilirubin ≤ 3 x LUN , AP ≤ 5 x LUN , ASAT ≤ 5 x LUN ) 8 . Adequate hematologic function : neutrophil ≥ 1.5 x 109/l , platelet ≥ 100 x 109/l , Hb ≥ 9,5 mg/dl 9 . Patient compliance geographic proximity allow proper staging , treatment followup . 10 . Women breastfeed use effective contraception sexually active , pregnant agree become pregnant participation trial 12 month thereafter . A negative pregnancy test inclusion trial require woman &lt; 50 year . Men agree father child participation trial 12 month thereafter . Exclusion criteria 1 . Pregnancy breastfeed woman 2 . Previous malignancy within 5 year concomitant malignancy , except : nonmelanomatous skin cancer adequately treat situ cervical cancer 3. neutrophil &lt; 1.5 x 109/l , platelet &lt; 100 x 109/l , Hb &lt; 9,5 mg/dl 4. bilirubin &gt; 3 x LUN , ALAT &gt; 5 x LUN , ASAT &gt; 5 x LUN 5 . Creatinine clearance &lt; 60 ml/min , calculate accord formula CockcroftGault 6 . Prior chemotherapy gemcitabine 7 . Severe uncontrolled cardiovascular disease ( congestive heart failure NYHA III IV , unstable angina pectoris , history myocardial infarction last 3 month , significant arrhythmia ) 8 . Psychiatric disorder preclude understanding information trial related topic give informed consent 9 . Active uncontrolled infection 10 . Preexisting peripheral neuropathy ( &gt; grade 1 ) 11 . Serious underlie medical condition ( judged investigator ) could impair ability patient participate trial ( e.g . uncontrolled diabetes mellitus , active autoimmune disease ) 12 . Concurrent treatment experimental drug anticancer therapy ; treatment clinical trial within 30 day prior trial entry 13 . Known hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>